Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases
Identifieur interne : 002972 ( Main/Exploration ); précédent : 002971; suivant : 002973Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases
Auteurs : Martin J. Hecht [Allemagne] ; Henning Stolze [Allemagne] ; Matthias Auf Dem Brinke [Allemagne] ; Ralf Giess [Allemagne] ; Thoams Treig [Allemagne] ; Martin Winterholler [Allemagne] ; Jörg Wissel [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-01-30.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Bontoxilysin, Botulinum Toxins, Type A (therapeutic use), Case study, Child, Female, HSP, Hereditary spastic paraplegia, Humans, Male, Middle Aged, Muscle Spasticity (drug therapy), Muscle Spasticity (etiology), Nervous system diseases, Neuromuscular Agents (therapeutic use), Spastic Paraplegia, Hereditary (complications), Spastic Paraplegia, Hereditary (drug therapy), Spasticity, Treatment, botulinum toxin A, hereditary spastic paraplegia, spasticity, therapy.
- MESH :
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- complications : Spastic Paraplegia, Hereditary.
- drug therapy : Muscle Spasticity, Spastic Paraplegia, Hereditary.
- etiology : Muscle Spasticity.
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged.
Abstract
Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21809
Affiliations:
- Allemagne
- Basse-Saxe, Bavière, District de Moyenne-Franconie, Schleswig-Holstein
- Erlangen, Hanovre, Kiel
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001A91
- to stream Istex, to step Curation: 001A91
- to stream Istex, to step Checkpoint: 001529
- to stream PubMed, to step Corpus: 002441
- to stream PubMed, to step Curation: 002441
- to stream PubMed, to step Checkpoint: 002407
- to stream Ncbi, to step Merge: 001F18
- to stream Ncbi, to step Curation: 001F18
- to stream Ncbi, to step Checkpoint: 001F18
- to stream Main, to step Merge: 003551
- to stream PascalFrancis, to step Corpus: 001387
- to stream PascalFrancis, to step Curation: 001932
- to stream PascalFrancis, to step Checkpoint: 001344
- to stream Main, to step Merge: 003952
- to stream Main, to step Curation: 002972
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title><author><name sortKey="Hecht, Martin J" sort="Hecht, Martin J" uniqKey="Hecht M" first="Martin J." last="Hecht">Martin J. Hecht</name></author><author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name></author><author><name sortKey="Auf Dem Brinke, Matthias" sort="Auf Dem Brinke, Matthias" uniqKey="Auf Dem Brinke M" first="Matthias" last="Auf Dem Brinke">Matthias Auf Dem Brinke</name></author><author><name sortKey="Giess, Ralf" sort="Giess, Ralf" uniqKey="Giess R" first="Ralf" last="Giess">Ralf Giess</name></author><author><name sortKey="Treig, Thoams" sort="Treig, Thoams" uniqKey="Treig T" first="Thoams" last="Treig">Thoams Treig</name></author><author><name sortKey="Winterholler, Martin" sort="Winterholler, Martin" uniqKey="Winterholler M" first="Martin" last="Winterholler">Martin Winterholler</name></author><author><name sortKey="Wissel, Jorg" sort="Wissel, Jorg" uniqKey="Wissel J" first="Jörg" last="Wissel">Jörg Wissel</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21809</idno><idno type="url">https://api.istex.fr/document/F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A91</idno><idno type="wicri:Area/Istex/Curation">001A91</idno><idno type="wicri:Area/Istex/Checkpoint">001529</idno><idno type="wicri:doubleKey">0885-3185:2008:Hecht M:botulinum:neurotoxin:type</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17999430</idno><idno type="wicri:Area/PubMed/Corpus">002441</idno><idno type="wicri:Area/PubMed/Curation">002441</idno><idno type="wicri:Area/PubMed/Checkpoint">002407</idno><idno type="wicri:Area/Ncbi/Merge">001F18</idno><idno type="wicri:Area/Ncbi/Curation">001F18</idno><idno type="wicri:Area/Ncbi/Checkpoint">001F18</idno><idno type="wicri:Area/Main/Merge">003551</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0133665</idno><idno type="wicri:Area/PascalFrancis/Corpus">001387</idno><idno type="wicri:Area/PascalFrancis/Curation">001932</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001344</idno><idno type="wicri:doubleKey">0885-3185:2008:Hecht M:botulinum:neurotoxin:type</idno><idno type="wicri:Area/Main/Merge">003952</idno><idno type="wicri:Area/Main/Curation">002972</idno><idno type="wicri:Area/Main/Exploration">002972</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title><author><name sortKey="Hecht, Martin J" sort="Hecht, Martin J" uniqKey="Hecht M" first="Martin J." last="Hecht">Martin J. Hecht</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University of Erlangen‐Nuremberg, Erlangen</wicri:regionArea><placeName><settlement type="city">Erlangen</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Moyenne-Franconie</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, BKH Kaufbeuren</wicri:regionArea><wicri:noRegion>BKH Kaufbeuren</wicri:noRegion><wicri:noRegion>BKH Kaufbeuren</wicri:noRegion></affiliation></author><author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University of Kiel, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Diako Hospital, Flensburg</wicri:regionArea><wicri:noRegion>Flensburg</wicri:noRegion><wicri:noRegion>Flensburg</wicri:noRegion></affiliation></author><author><name sortKey="Auf Dem Brinke, Matthias" sort="Auf Dem Brinke, Matthias" uniqKey="Auf Dem Brinke M" first="Matthias" last="Auf Dem Brinke">Matthias Auf Dem Brinke</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurological Rehabilitation, Bad Wildungen</wicri:regionArea><wicri:noRegion>Bad Wildungen</wicri:noRegion><wicri:noRegion>Bad Wildungen</wicri:noRegion></affiliation></author><author><name sortKey="Giess, Ralf" sort="Giess, Ralf" uniqKey="Giess R" first="Ralf" last="Giess">Ralf Giess</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Henriettenstiftung, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Treig, Thoams" sort="Treig, Thoams" uniqKey="Treig T" first="Thoams" last="Treig">Thoams Treig</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Neurological Rehabilitation Centre, Ernst‐Moritz‐Arndt University, Greifswald</wicri:regionArea><wicri:noRegion>Greifswald</wicri:noRegion><wicri:noRegion>Greifswald</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Neurological Rehabilitation Centre, Schwarzwaldkliniken, Bad Krozingen</wicri:regionArea><wicri:noRegion>Bad Krozingen</wicri:noRegion><wicri:noRegion>Bad Krozingen</wicri:noRegion></affiliation></author><author><name sortKey="Winterholler, Martin" sort="Winterholler, Martin" uniqKey="Winterholler M" first="Martin" last="Winterholler">Martin Winterholler</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Rummelsberger Kliniken, Schwarzenbruck</wicri:regionArea><wicri:noRegion>Schwarzenbruck</wicri:noRegion><wicri:noRegion>Schwarzenbruck</wicri:noRegion></affiliation></author><author><name sortKey="Wissel, Jorg" sort="Wissel, Jorg" uniqKey="Wissel J" first="Jörg" last="Wissel">Jörg Wissel</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurological Rehabilitation, Beelitz Heilstätten, Beelitz</wicri:regionArea><wicri:noRegion>Beelitz</wicri:noRegion><wicri:noRegion>Beelitz</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-01-30">2008-01-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="228">228</biblScope><biblScope unit="page" to="233">233</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F</idno><idno type="DOI">10.1002/mds.21809</idno><idno type="ArticleID">MDS21809</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Bontoxilysin</term><term>Botulinum Toxins, Type A (therapeutic use)</term><term>Case study</term><term>Child</term><term>Female</term><term>HSP</term><term>Hereditary spastic paraplegia</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Muscle Spasticity (drug therapy)</term><term>Muscle Spasticity (etiology)</term><term>Nervous system diseases</term><term>Neuromuscular Agents (therapeutic use)</term><term>Spastic Paraplegia, Hereditary (complications)</term><term>Spastic Paraplegia, Hereditary (drug therapy)</term><term>Spasticity</term><term>Treatment</term><term>botulinum toxin A</term><term>hereditary spastic paraplegia</term><term>spasticity</term><term>therapy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Spastic Paraplegia, Hereditary</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Muscle Spasticity</term><term>Spastic Paraplegia, Hereditary</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Muscle Spasticity</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Etude cas</term><term>Hypertonie spastique</term><term>Paraplégie spasmodique héréditaire de Strümpell-Lorrain</term><term>Pathologie du système nerveux</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Basse-Saxe</li><li>Bavière</li><li>District de Moyenne-Franconie</li><li>Schleswig-Holstein</li></region><settlement><li>Erlangen</li><li>Hanovre</li><li>Kiel</li></settlement></list><tree><country name="Allemagne"><region name="Bavière"><name sortKey="Hecht, Martin J" sort="Hecht, Martin J" uniqKey="Hecht M" first="Martin J." last="Hecht">Martin J. Hecht</name></region><name sortKey="Auf Dem Brinke, Matthias" sort="Auf Dem Brinke, Matthias" uniqKey="Auf Dem Brinke M" first="Matthias" last="Auf Dem Brinke">Matthias Auf Dem Brinke</name><name sortKey="Giess, Ralf" sort="Giess, Ralf" uniqKey="Giess R" first="Ralf" last="Giess">Ralf Giess</name><name sortKey="Hecht, Martin J" sort="Hecht, Martin J" uniqKey="Hecht M" first="Martin J." last="Hecht">Martin J. Hecht</name><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name><name sortKey="Treig, Thoams" sort="Treig, Thoams" uniqKey="Treig T" first="Thoams" last="Treig">Thoams Treig</name><name sortKey="Treig, Thoams" sort="Treig, Thoams" uniqKey="Treig T" first="Thoams" last="Treig">Thoams Treig</name><name sortKey="Winterholler, Martin" sort="Winterholler, Martin" uniqKey="Winterholler M" first="Martin" last="Winterholler">Martin Winterholler</name><name sortKey="Wissel, Jorg" sort="Wissel, Jorg" uniqKey="Wissel J" first="Jörg" last="Wissel">Jörg Wissel</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002972 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002972 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F
|texte= Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases
}}
| This area was generated with Dilib version V0.6.23. |  |